Webcast Alert: Isis Pharmaceuticals Announces Second Quarter 2008 Financial Results...

* Reuters is not responsible for the content in this press release.

Thu Jul 31, 2008 7:02am EDT 

Webcast Alert: Isis Pharmaceuticals Announces Second Quarter 2008 Financial
Results Conference Call

CARLSBAD, Calif., July 31, 2008 (PRIME NEWSWIRE) -- Isis Pharmaceuticals, Inc.
(Nasdaq:ISIS) announces the following webcast:

 What:     Isis Pharmaceuticals' Second Quarter 2008 Financial Results

 When:     Thursday, August 7, 2008, at 8:30 a.m. ET / 5:30 a.m. PT

 Where:    www.isispharm.com

 How:      Live on the Internet.  Simply log onto our website listed
           above.

 Contacts: Kristina Lemonidis
           Associate Director, Corporate Development 
           (760) 603-2490

           Amy Blackley, Ph.D.
           Manager, Corporate Communications
           (760) 603-2772
If you are unable to participate during the live event, a replay of the webcast
will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for
its product pipeline and for its partners. The Company has successfully
commercialized the world's first antisense drug and has 18 drugs in development.
Isis' drug development programs are focused on treating cardiovascular and
metabolic diseases. Isis' partners are developing antisense drugs invented by
Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis'
majority-owned subsidiary, is developing and commercializing the Ibis T5000(tm)
Biosensor System, a revolutionary system to identify infectious organisms. Isis
is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the
discovery, development and commercialization of microRNA therapeutics. As an
innovator in RNA-based drug discovery and development, Isis is the owner or
exclusive licensee of over 1,500 issued patents worldwide. Additional
information about Isis is available at www.isispharm.com.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.